Adult ALL Treatment at Diagnosis

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The present study has been designed to give participating centers the possibility of better understanding the diagnostic and prognostic factors of ALL patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
• Treatments: Asparaginase; Daunorubicin; Methotrexate; Vincristine

Criteria

Inclusion Criteria:

• Diagnosis of acute lymphoblastic leukemia (ALL)

• Negative myeloperoxidase stain

• Phenotype T (ALL-T) and B(ALL-B)

Exclusion Criteria:

• Creatinine > 2.5mg/dL after adequate hydratation

• LVEF <50%

• Presence of documented infections not responding to antibiotic and/or antifungal therapy

• Presence of concomitant malignant diseases

• Absence of any psychological condition that does not allow to intake high doses of cortisone

• Patients who have received any antineoplastic chemiotherapy for more than 5 days

• Patients who have received any steroids for more than 10 days